88IV - PR Newswire Asia's news


Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599 The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration ... 2026-08-04T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination -Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and ... 2026-08-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model SHANGHAI , Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced ... 2026-08-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical ... 2026-08-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth Former Samsung Group and Samsung Electronics executive who led corporate growth strategy and major global M&A initiatives across the Corporate Strategy Office and DX Division Brings extensive ... 2026-07-31T Biotechnology Cosmetics & Personal Care Health Care/Hospital Medical Equipment
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand SHANGHAI , July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial HANGZHOU, China , July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Telix H1 2026 Results: Investor Webcast Notification MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results ... 2026-07-31T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research ... 2026-07-30T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology